Author: Business Wire

ソウル半導体、自然光LEDの”SunLike”で世界初の高いアイセーフティ認証

韓国安山市–(BUSINESS WIRE)–(ビジネスワイヤ) — 世界的なLED (発光ダイオード)専業メーカーのSeoul Semiconductor Co., Ltd. (本社:韓国安山市、代表理事:李貞勲、以下「ソウル半導体」)は、太陽の光に最も近い光を発するLEDの”SunLike”が、光源の安全性に関するアイセーフティ認証でRG-1の評価を受け、最高レベルの安全性が認められたと明らかにした。 アイセーフティ認証は、LEDから発せられる波長を分析して、安全性に基づいて等級分けされる認証である。照明の安全性の優先度が非常に高い欧州地域では、アイセーフティ認証が不可欠であり、目で直接見たときに、視力に危険を及ぼす可能性のあるリスクグループ3 (RG-3)以下の光源については、完成品に警告文を記述することを義務化している。 SunLikeは、東芝マテリアル株式会社(本社:神奈川県横浜市、代表取締役社長:青木 克明)のTRI-R技術を応用した自然光LEDで、このたびアイセーフティ認証でRG-1の等級を受けた。 RG-1は、当該光源の下で一生生活を続けても生体学的な危険がない安

Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan

IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced the commencement of patient dosing in its Phase 2 clinical trial designed in accordance with the requirements of Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) for poten

NovaBay Pharmaceuticals Reports Third Quarter 2017 Financial Results

EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for lid and lash hygiene in the domestic eye care market, reports financial results for the three and ninth months ended September 30, 2017 and provides a business update. “First off, we are significantly better positioned to support continued Avenova growth having entered into a $10.3 million financing with accredited investors

Aerpio Reports Third Quarter 2017 Financial Results

CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the third quarter ended September 30, 2017. “Aerpio has made tremendous progress in recent months towards the Company’s vision of becoming a leader in developing and commercializing first-in-class treatments for sight-threatening diseases,” said Dr. Joseph Gardner, Chief Executive Officer. “We

Aerpio Reports Third Quarter 2017 Financial Results

CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the third quarter ended September 30, 2017. “Aerpio has made tremendous progress in recent months towards the Company’s vision of becoming a leader in developing and commercializing first-in-class treatments for sight-threatening diseases,” said Dr. Joseph Gardner, Chief Executive Officer. “We

RiboQuark Pharmaceutical Technology Co., Ltd., Announces Enrollment of The First Ever Patient in China for a Pivotal Clinical Trial with a siRNA Drug Candidate as Part of a Global Clinical Study of the Ocular Neuroprotectant QPI-1007

KUNSHAN, China–(BUSINESS WIRE)–Kunshan RiboQuark Pharmaceutical Technology Co., Ltd. (“RiboQuark”), a Chinese-foreign equity joint venture and clinical stage pharmaceutical company established by Suzhou Ribo Life Science Co., Ltd. (“Ribo”) and Quark Pharmaceuticals Inc., announced today enrollment of the first patient in China in QRK207, a global pivotal Phase II/III study of the ocular neuroprotectant QPI-1007. QPI-1007 is a synthetic siRNA designed to temporarily inhibit expression of the p

Samenvatting: Novaliq kondigt randomisatie fase 2b/3 van onderzoek ESSENCE naar CyclASol® voor behandeling van symptomen droge ogen

HEIDELBERG, Duitsland–(BUSINESS WIRE)–Novaliq GmbH, een gespecialiseerd farmaceutisch bedrijf met een revolutionair platform voor medicijntoediening dat slecht oplosbare geneesmiddelen verandert in effectieve oogheelkundige therapieën, heeft vandaag bekendgemaakt dat het is begonnen met de randomisatie van patiënten die meedoen aan fase2b/3 van het onderzoek ESSENCE, naar de behandeling van symptomen rond droge ogen met CyclASol®. Droge ogen vormen een complexe ziekte aan het oogoppervlak met

Resumen: Novaliq anuncia la selección aleatoria del primer paciente para su ensayo clínico ESSENCE fase 2b/3 de CyclASol® para el tratamiento de los signos y síntomas del síndrome de ojo seco

HEIDELBERG, Alemania–(BUSINESS WIRE)–Novaliq GmbH, una compañía de administración de fármacos especializada en la aplicación tópica de tecnologías oftalmológicas para medicamentos poco solubles, ha anunciado el inicio de la selección aleatoria de pacientes para su ensayo clínico ESSENCE fase 2b/3 que evaluará CyclASol® para el tratamiento de los signos y síntomas del síndrome del ojo seco (DED). El comunicado en el idioma original, es la versión oficial y autorizada del mismo. La traducción e